Drug Profile
Human papillomavirus recombinant vaccine nonavalent - Shanghai Bovax Biotechnology
Alternative Names: 9-valent HPV recombinant vaccine - Shanghai Bovax Biotechnology; 9-valent HPV vaccine - Shanghai Bovax Biotechnology; 9vHPV vaccineLatest Information Update: 24 Oct 2022
Price :
$50
*
At a glance
- Originator Shanghai Bovax Biotechnology
- Developer Chongqing Bovax Biopharmaceutical; Shanghai Bovax Biotechnology
- Class Papillomavirus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Human papillomavirus infections
Most Recent Events
- 23 Sep 2022 Shanghai Bovax Biotechnology initiates a phase I trial in Human papillomavirus infections (Prevention, In children, In adolescents, In adults) in China (Parenteral) (NCT05518201)
- 06 Sep 2021 Shanghai Bovax Biotechnology and Chongqing Bovax Biopharmaceutical complete a phase III trial in Human papillomavirus infections (Prevention, In adults) in China (Parenteral) (NCT04425291)
- 16 Jul 2021 Shanghai Bovax Biotechnology in collaboration with Chongqing Bovax Biopharmaceutical completes a phase III clinical trials in Human papillomavirus infections (In children, In adults, In volunteers, Prevention) in China (Parenteral) (NCT05372016)